Drug profile · INN
capivasertib
TRUQAP
capivasertib (TRUQAP) is a serine/threonine-protein kinase akt inhibitor. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
Drug details — capivasertib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 1
- Programs
- 14
- Data quality
- 0.84
Quick answer
capivasertib (TRUQAP) is a serine/threonine-protein kinase akt inhibitor. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serine/threonine-protein kinase AKT inhibitor
Primary target: Serine/threonine-protein kinase AKT
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| NMPA | clinical trials | — |
Recent coverage
FDA Approves Capivasertib for PTEN-Deficient Prostate Cancer
FDA Approves Capivasertib for PTEN-Deficient prostate cancer, expanding TRUQAP into a new oncology setting. The approval pairs capivasertib with abiraterone and prednisone for adults with PTEN-deficient metastatic androgen pathway modulation-naive or sensitive disease.
FDA approves capivasertib plus abiraterone and prednisone in PTEN-deficient mHSPC
The FDA approved capivasertib plus abiraterone and prednisone for adult patients with PTEN-deficient metastatic androgen pathway modulation-naïve or sensitive prostate cancer. The move creates a new catalyst for AstraZeneca’s Truqap and adds a biomarker-defined prostate cancer use to track.
Truqap gains US approval in PTEN-deficient metastatic prostate cancer
AstraZeneca’s Truqap (capivasertib) has been approved in the US with abiraterone and prednisone for PTEN-deficient metastatic prostate cancer. The move creates a first-in-class targeted option and a new catalyst to watch for BD teams, investors, and analysts.
FDA Advisory Committee Recommends AstraZeneca's TRUQAP for PTEN-Deficient Prostate Cancer
FDA Advisory Committee votes 7-1 to recommend AstraZeneca's TRUQAP (capivasertib) for PTEN-deficient metastatic hormone-sensitive prostate cancer patients.
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is capivasertib?
capivasertib (TRUQAP) is a serine/threonine-protein kinase akt inhibitor. Associated with AstraZeneca. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for capivasertib?
TRUQAP is a marketed brand name for capivasertib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of capivasertib?
capivasertib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.